At a Glance What It Is & Composition Semaglutide is a single-molecule GLP-1 receptor agonist an analogue of human GLP-1 engineered for a long half-life (about a week), which is what allows once-weekly rather than daily dosing
This gives your body time to adjust at each stage
(2021) "Once-weekly semaglutide in adults with overweight or obesity" The New England Journal of Medicine, 384(11) This article was reviewed and approved by Lujain Alhassan, Bariatric Nutritionist, and Alice Fletcher, Lead Bariatric Dietitian, on 7 July 2025
In clinical trials, Semaglutide GLP-1 has been studied for different durations, ranging from 16 to 68 weeks, with varying dosages
[18] Patients should be counseled that early results, while encouraging, do not predict final outcomes